SpringWorks Therapeutics, Inc. Common Stock

SWTX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
SWTX Income Statement
SWTX Balance Sheet
SWTX Cash Flow
Congress Trading

Recent trades of SWTX by members of U.S. Congress

Politician Type Traded
Josh Gottheimer House / D Purchase $1,001 - $15,000 Jul. 19, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Jun. 18, 2024
Josh Gottheimer House / D Purchase $1,001 - $15,000 May. 09, 2024
Chris Jacobs House / R Purchase $1,001 - $15,000 Dec. 12, 2022
SWTX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
SWTX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
SWTX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by SWTX's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Treatments with nirogacestat Nov. 12, 2024
  • Patent Title: Synthesis of nirogacestat Oct. 08, 2024
  • Patent Title: Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof Sep. 17, 2024
  • Patent Title: Treatments with nirogacestat Jul. 16, 2024
  • Patent Title: 2-pyrazole anilines and related analogs for inhibiting yap/taz-tead Jul. 09, 2024
  • Patent Title: Dosage forms of mirdametinib Jul. 09, 2024
  • Patent Title: Treatments with nirogacestat Jun. 18, 2024
  • Patent Title: Treatments with nirogacestat Jun. 18, 2024
  • Patent Title: Treatment of neurofibromatosis type 1 (nf1) associated plexiform neurofibromas (pn) in pediatric patients with mirdametinib Jun. 18, 2024
  • Patent Title: Treatments with nirogacestat Apr. 16, 2024
  • Patent Title: Treatments with nirogacestat Apr. 09, 2024
  • Patent Title: Treatments with nirogacestat Mar. 26, 2024
  • Patent Title: Treatments with nirogacestat Mar. 12, 2024
  • Patent Title: Treatments with nirogacestat Mar. 12, 2024
  • Patent Title: Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof Jan. 30, 2024
  • Patent Title: Mirdametinib treatment Jan. 30, 2024
  • Patent Title: Treatments with nirogacestat Jan. 16, 2024
  • Patent Title: Chlorinated tetralin compounds and pharmaceutical compositions Dec. 19, 2023
  • Patent Title: Mirdametinib treatment Dec. 12, 2023
  • Patent Title: Treatment of neurofibromatosis type 1 (nf1) associated plexiform neurofibromas (pn) in pediatric patients with mirdametinib Nov. 21, 2023
  • Patent Title: Chlorinated tetralin compounds and pharmaceutical compositions Nov. 07, 2023
  • Patent Title: Mirdametinib treatment Nov. 07, 2023
  • Patent Title: Non-linear dosing of mirdametinib Nov. 07, 2023
  • Patent Title: Fluorinated phenylamino compounds and pharmaceutical compositions Oct. 10, 2023
  • Patent Title: Dispersible formulations of n-((r)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof Feb. 07, 2023
  • Patent Title: Solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof Aug. 30, 2022
  • Patent Title: Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof Aug. 10, 2021
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of SWTX in WallStreetBets Daily Discussion

SWTX News

Recent insights relating to SWTX

CNBC Recommendations

Recent picks made for SWTX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SWTX

SWTX Top Shareholders
Shareholder
Shares Held
SWTX Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

SWTX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view SWTX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top